MannKind (MannKind) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is MannKind Dividend Payout Ratio?

MannKind's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for MannKind's Dividend Payout Ratio or its related term are showing as below:

MNKD's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-28), the Dividend Yield % of MannKind is 0.00%.

MannKind's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

MannKind Dividend Payout Ratio Historical Data

The historical data trend for MannKind's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Dividend Payout Ratio Chart

MannKind Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

MannKind Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of MannKind's Dividend Payout Ratio

For the Biotechnology subindustry, MannKind's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MannKind's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MannKind's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where MannKind's Dividend Payout Ratio falls into.

MannKind Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

MannKind's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-0.034
	=	N/A

MannKind's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0.021
	=	0.00

MannKind (NAS:MNKD) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

MannKind Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of MannKind's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (MannKind) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

NNFN:Germany

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Executives

Michael Castagna	officer: Chief Commercial Officer	25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson	officer: VP & Assoc General Counsel	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder	officer: Chief Financial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank	officer: EVP Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: EVP Chief Operating Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh	officer: EVP Technical Operations	1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo	officer: Chief Commercial Officer	30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross	officer: Corp VP, Chief People Officer	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio	director	30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur	director
Sabrina Kay	director	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall	officer: Chief Medical Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley	officer: Chief Commercial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney	officer: Chief Compliance Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362